approval
saveBLINCYTO (BLINATUMOMAB) — FDA approval
community read0 votes
Sponsor: AMGEN. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 2 completionAbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026 · 154d ago
- phase 2 completionSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)Apr 25, 2026 · 159d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalOct 21, 2025 · 345d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalApr 29, 2025 · 520d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalDec 17, 2024 · 653d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 14, 2024 · 839d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalFeb 8, 2024 · 966d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1199d ago
same company · ±60 days · 5
- approvalblinatumomab: BLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023
- approvalENBREL (ETANERCEPT) — FDA approvalJun 9, 2023
- approvalAMJEVITA: AMJEVITA (ADALIMUMAB-ATTO) — FDA approvalJul 12, 2023
- approvalapremilast: OTEZLA (APREMILAST) — FDA approvalJul 20, 2023
- approvalAMJEVITA: AMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAug 14, 2023
comments(0)
5-min edit window · permanent after that